American Oncology Network Partners with Evolent to Eliminate Prior Authorization in Cancer Care

Reuters
2025/11/07
<a href="https://laohu8.com/S/AONC">American Oncology Network</a> Partners with Evolent to Eliminate Prior Authorization in Cancer Care

American Oncology Network Inc. $(AON)$ and Evolent Health, Inc. have announced a new national partnership aimed at improving cancer care delivery. The collaboration introduces an innovative model designed to provide high-quality, more affordable, and connected cancer care without the need for prior authorization. Key components of the program include quality initiatives to enhance care across the continuum, the use of provider education and incentives, and AI-driven clinical insights powered by the MiBA data and analytics platform. Providers demonstrating adherence to quality standards will be "gold-carded," exempting them from most prior authorization requirements. The partnership also seeks to support patients through enhanced care navigation and connectivity with their oncology teams, with the model set to roll out in select markets in the coming year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. American Oncology Network Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10